Journal Article10.1016/J.CLD.2004.04.014
Nonalcoholic Fatty Liver Disease
TL;DR: AASLD consensus guidelines require the presence of liver injury in the form of ballooning to distinguish NASH from other disorders of the NAFLD disease spectrum as discussed by the authors, which is defined by fat deposition in the liver in absence of secondary causes for steatosis.
read more
About: This article is published in Clinics in Liver Disease. The article was published on 01 Aug 2004. The article focuses on the topics: Fatty liver & Nonalcoholic fatty liver disease.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers
Geary W. Olsen,Larry R. Zobel +1 more
TL;DR: There was no evidence that employees’ serum PFOA concentrations were associated with total cholesterol or LDL, and several explanations are offered for the inconsistent triglyceride associations with PFO a including both methodological as well as biological possibilities.
The role of fatty acids in the development and progression of nonalcoholic fatty liver disease
TL;DR: Data suggest that saturated fatty acids may represent an intrinsic second hit to the liver that hastens the development of NASH.
Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis.
Lars P. Bechmann,Robert K. Gieseler,Jan-Peter Sowa,Alisan Kahraman,Jochen Erhard,Inga Wedemeyer,Barbara Emons,Christoph Jochum,Thorsten Feldkamp,Guido Gerken,Ali Canbay +10 more
TL;DR: The effect of obesity on free fatty acid levels, fatty acid transport proteins (FATPs) and on extrinsic and intrinsic activation of apoptosis in the liver is studied.
106
Nonalcoholic steatohepatitis (nash) with diabetes: predictors of liver fibrosis
Deepak Amarapurkar,Anjali D Amarapurkar,Nikhil Patel,Subhash Agal,R. Baigal,Parijat Gupte,Pramanik Ss +6 more
TL;DR: There is no definite noninvasive test that helps to predict liver fibrosis however AST, ALT levels and AST: ALT ratio may help to determine the fibrosis in patients of NASH with diabetes in majority of cases.
96
Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A2-knockout mice.
Hiromi,Naoki Yokoyama,Shintaro Yoshida,Kae Tsutsumi,Shinji Hatakeyama,Takashi Sato,Keiichi Ishihara,Satoshi Akiba +7 more
TL;DR: It is suggested that a deficiency of IVA-PLA2 alleviates fatty liver damage caused by high-fat diets, probably because of the lower generation of IV a phospholipase A2 metabolites, such as prostaglandin E2.
References
Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse
TL;DR: It is shown that overexpression of suppressors of cytokine signaling (SOCS)-1 and SOCS-3 in liver causes insulin resistance and an increase in the key regulator of fatty acid synthesis in liver, sterol regulatory element-binding protein (SREBP)-1c.
400
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
Heather Patton,Keyur Patel,Keyur Patel,Cynthia Behling,David J. Bylund,Lawrence M. Blatt,Marc Vallee,Shanon Heaton,Andrew Conrad,Paul J. Pockros,John G. McHutchison,John G. McHutchison +11 more
TL;DR: Steatosis is an important cofactor in hepatitis C as it is associated with fibrosis and reduces the likelihood of achieving early and sustained virologic response in genotype 1 infected patients.
395
Lipoapoptosis: its mechanism and its diseases.
Roger H Unger,Lelio Orci +1 more
TL;DR: It is suggested that some of the components of the metabolic syndrome of obese humans and the sarcopenia of aging may be result of failure of leptin liporegulation to prevent lipid overload of lean body mass and lipoapoptosis in certain organ systems.
393
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
Thierry Poynard,Vlad Ratziu,Sylvie Naveau,Dominique Thabut,Frédéric Charlotte,Djamila Messous,Dominique Capron,Annie Abella,J. Massard,Yen Ngo,Mona Munteanu,A. Mercadier,Michael Manns,Janice K. Albrecht +13 more
TL;DR: SteatoTest is a simple and non-invasive quantitative estimate of liver steatosis and may reduce the need for liver biopsy, particularly in patients with metabolic risk factor.
Update on nonalcoholic fatty liver disease.
TL;DR: Treatment consists of managing the comorbidities: obesity, diabetes, and hyperlipidemia, and ursodeoxycholic acid is the only drug that has shown benefit and is the most promising of the drugs currently being investigated.
378
Related Papers (5)
Aradhna Seth,Maya Balakrishnan +1 more
- 01 Jan 2017
Nidhi P. Goyal,Jeffrey B. Schwimmer +1 more
- 01 Jan 2014